AngioDynamics (NASDAQ:ANGO – Get Free Report) and Allurion Technologies (NYSE:ALUR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.
Volatility and Risk
AngioDynamics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for AngioDynamics and Allurion Technologies, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AngioDynamics | 0 | 0 | 4 | 0 | 3.00 |
Allurion Technologies | 0 | 0 | 2 | 0 | 3.00 |
Valuation & Earnings
This table compares AngioDynamics and Allurion Technologies’ revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AngioDynamics | $338.75 million | 0.75 | -$52.44 million | ($4.84) | -1.31 |
Allurion Technologies | $53.47 million | 2.00 | -$80.61 million | N/A | N/A |
AngioDynamics has higher revenue and earnings than Allurion Technologies.
Insider & Institutional Ownership
89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 5.1% of AngioDynamics shares are held by insiders. Comparatively, 20.0% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares AngioDynamics and Allurion Technologies’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
AngioDynamics | -60.21% | -3.48% | -2.68% |
Allurion Technologies | N/A | N/A | -97.97% |
Summary
AngioDynamics beats Allurion Technologies on 6 of the 11 factors compared between the two stocks.
About AngioDynamics
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.